As a Chinese endemic species with dual medicinal–industrial importance, Eucommia ulmoides faces habitat challenges under climate change. Using 21 bioclimatic variables and 704 occurrence records, we modeled current and future (2021–2100) distributions via MaxEnt 3.4.4 and ArcGIS 10.8. The results indicate the following: (1) current optimal habitats cluster in the mid-elevation valleys of Daba–Wuling Mountains (Guizhou–Chongqing core); (2) SSP5-8.5 projections suggest a 19.2% reduction in high-suitability areas by 2081–2100 versus SSP1-2.6; and (3) distribution centroids migrate southward under both scenarios. Our multi-temporal analysis provides actionable intelligence for ex situ conservation and agroforestry planning.

To investigate how sweating–drying processing affects the components, antioxidant activity, and hepatoprotective mechanisms of Eucommia ulmoides (EUB) against acute liver injury (ALI), this study constructed a “processing–active components–ALI targets” network. Eight processed EUB samples were analyzed using HPLC fingerprinting, multi-assay antioxidant tests (DPPH/ABTS·+/pyrogallol), network pharmacology, and molecular docking. Sweating–drying significantly altered EUB’s chemical profile, with HPLC fingerprint similarities ranging from 0.715 to 1.000, the lowest being for FG4 (40 °C dried after sweating) and FD (freeze-dried after sweating). Key components (chlorogenic acid (CA), pinoresinol diglucoside (PDG), aucubin (AU), geniposidic acid (GPA)) varied: XS (sun-dried) had the highest CA/PDG, while FG4 showed increased AU/GPA. FY (shade-dried after sweating) exhibited the strongest free radical scavenging (DPPH/ABTS·+/pyrogallol IC₅₀ = 0.828, 0.134, 14.200 mg/mL), which correlated with CA/PDG/liriodendrin (PD) synergy. Network pharmacology identified 205 EUB-ALI intersection targets (core: TNF, PTGS2, GAPDH) and the AGE-RAGE pathway; molecular docking confirmed strong CA/PDG binding to GAPDH/PTGS2. This study clarifies how processing regulates EUB’s components and their links to antioxidant and hepatoprotective effects, providing scientific support for EUB’s clinical application against ALI.